Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Non-Hodgkin 2

Interventions

Rituximab 56Cyclophosphamide 39fludarabine 23fludarabine phosphate 18Peripheral Blood Stem Cell Transplantation 17Lenalidomide 14Melphalan 13Etoposide 12venetoclax 11Whole-Body Irradiation 11Mycophenolic Acid 11obinutuzumab 10Vincristine 10Prednisone 10Bendamustine Hydrochloride 10Doxorubicin 9Cytarabine 9Cyclosporine 9Bortezomib 9Filgrastim 8pembrolizumab 7Nivolumab 7Gemcitabine 7Busulfan 7acalabrutinib 6Tacrolimus 6Interleukin-2 6Dexamethasone 6Carmustine 6Alemtuzumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Non-Hodgkin × galiximab × Clear all
NCT00048555 2013-09-16

Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma

Biogen

Phase 1/2 Completed
90 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT00575068 2012-06-08

Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma

Biogen

Phase 1/2 Completed
42 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡